Evidence map›Paper›PMID 34878928›Full record

ArticleThe Journal of international medical research2021

Primary retroperitoneal liposarcoma: a rare case report.

Shu Wang, Xu Han, Shiyang Liu, Guangmeng Xu, Jiannan Li

Open access · goldAbstract readCase Reports
In one paragraph

Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shu WangDepartment of Radiotherapy, The Second Hospital of Jilin University, Changchun Jilin, China.
Xu HanDepartment of General Surgery, The Second Hospital of Jilin University, Changchun Jilin, China.
Shiyang LiuDepartment of Vascular Surgery, The Second Hospital of Jilin University, Changchun Jilin, China.
Guangmeng XuDepartment of General Surgery, The Second Hospital of Jilin University, Changchun Jilin, China.
Jiannan LiDepartment of General Surgery, The Second Hospital of Jilin University, Changchun Jilin, China.ORCID https://orcid.org/0000-0001-9744-7666
Second Affiliated Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary retroperitoneal liposarcoma (PRPLS) is a rare malignant tumor with a low incidence. A 34-year-old female patient presented to our department with abdominal pain, nausea, and vomiting for 2 days. Abdominal computed tomography (CT) indicated a huge mass between the liver and kidney, with a clear boundary and measuring approximately 202 mm × 155 mm ×106 mm. The mass was considered a retroperitoneal lipoma or liposarcoma. The entire tumor was completely resected without auxiliary injury, and histopathology of the resected specimen indicated liposarcoma. The patient recovered well and was discharged from our department on the 6th postoperative day. No signs of relapse were seen during 1-year of follow-up. PRPLS is rare and without obvious symptoms in the early stage. CT plays a vital role in the diagnosis of PRPLS, and surgical resection is considered the most suitable treatment. Radiotherapy and chemotherapy might also be treatment options to improve the overall survival of PRPLS patients.

Indexed as

LiposarcomaRetroperitoneal NeoplasmsAdultFemaleHumansRetroperitoneal SpaceTomography, X-Ray Computedchemotherapycomputed tomographydiagnosishistopathologymalignantPrimary retroperitoneal liposarcomaradiotherapysurgery

Identifiers

PMID34878928
PMCPMC8664316
OpenAlexW4200602914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.